OpenURL Connection Search

Select item for more details and to access through your institution.

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Published in:
Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00996-x
By:
- Tiong, Ing Soo;
- Wall, Meaghan;
- Bajel, Ashish;
- Kalro, Akash;
- Fleming, Shaun;
- Roberts, Andrew W.;
- Thiagarajah, Nisha;
- Chua, Chong Chyn;
- Latimer, Maya;
- Yeung, David;
- Marlton, Paula;
- Johnston, Amanda;
- Enjeti, Anoop;
- Fong, Chun Yew;
- Cull, Gavin;
- Larsen, Stephen;
- Kennedy, Glen;
- Schwarer, Anthony;
- Kipp, David;
- Ramanathan, Sundra
Publication type:
Article
Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia.
Published in:
British Journal of Haematology, 2021, v. 192, n. 6, p. 1026, doi. 10.1111/bjh.16722
By:
- Tiong, Ing S.;
- Dillon, Richard;
- Ivey, Adam;
- Teh, Tse‐Chieh;
- Nguyen, Phillip;
- Cummings, Nicholas;
- Taussig, David C.;
- Latif, Annie‐Louise;
- Potter, Nicola E.;
- Runglall, Manohursingh;
- Russell, Nigel H.;
- Raj, Kavita;
- Schwarer, Anthony P.;
- Fong, Chun Yew;
- Grigg, Andrew P.;
- Wei, Andrew H.
Publication type:
Article
Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B‐acute lymphoblastic leukaemia.
Published in:
British Journal of Haematology, 2020, v. 191, n. 1, p. 123, doi. 10.1111/bjh.16949
By:
- Ryland, Georgina L.;
- Barraclough, Allison;
- Fong, Chun Yew;
- Fleming, Shaun;
- Bajel, Ashish;
- Hofmann, Oliver;
- Westerman, David;
- Grimmond, Sean;
- Blombery, Piers
Publication type:
Article
MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S343, doi. 10.1016/S2152-2650(21)01798-5
By:
- Wei, Andrew H.;
- Garcia, Jacqueline S.;
- Borate, Uma;
- Chun Yew Fong;
- Baer, Maria R.;
- Nowak, Daniel;
- Peterlin, Pierre;
- Jurcic, Joseph;
- Jacoby, Meagan A.;
- Platzbecker, Uwe;
- Odenike, Olatoyosi;
- Cunningham, Ilona;
- Ying Zhou;
- Hoffman, David;
- Hogdal, Leah;
- Naqvi, Kiran;
- Kye, Steve;
- Garcia-Manero, Guillermo
Publication type:
Article
Poster: MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results.
Published in:
Clinical Lymphoma, Myeloma & Leukemia, 2021, v. 21, p. S227, doi. 10.1016/S2152-2650(21)01429-4
By:
- Wei, Andrew H.;
- Garcia, Jacqueline S.;
- Borate, Uma;
- Chun Yew Fong;
- Baer, Maria R.;
- Nowak, Daniel;
- Peterlin, Pierre;
- Jurcic, Joseph;
- Jacoby, Meagan A.;
- Platzbecker, Uwe;
- Odenike, Olatoyosi;
- Cunningham, Ilona;
- Ying Zhou;
- Hoffman, David;
- Hogdal, Leah;
- Naqvi, Kiran;
- Kye, Steve;
- Garcia-Manero, Guillermo
Publication type:
Article
CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting.
Published in:
PLoS ONE, 2024, v. 19, n. 9, p. 1, doi. 10.1371/journal.pone.0310641
By:
- Lim, Kelly;
- Kan, Winnie L.;
- Nair, Pramod C.;
- Kutyna, Monika;
- Lopez, Angel F.;
- Hercus, Timothy;
- Ross, David M.;
- Lane, Steven;
- Fong, Chun Yew;
- Brown, Anna;
- Yong, Agnes;
- Yeung, David;
- Hughes, Timothy;
- Hiwase, Devendra;
- Thomas, Daniel
Publication type:
Article
BET inhibitor resistance emerges from leukaemia stem cells.
Published in:
Nature, 2015, v. 525, n. 7570, p. 538, doi. 10.1038/nature14888
By:
- Fong, Chun Yew;
- Gilan, Omer;
- Lam, Enid Y. N.;
- Rubin, Alan F.;
- Ftouni, Sarah;
- Tyler, Dean;
- Stanley, Kym;
- Sinha, Devbarna;
- Yeh, Paul;
- Morison, Jessica;
- Giotopoulos, George;
- Lugo, Dave;
- Jeffrey, Philip;
- Lee, Stanley Chun-Wei;
- Carpenter, Christopher;
- Gregory, Richard;
- Ramsay, Robert G.;
- Lane, Steven W.;
- Abdel-Wahab, Omar;
- Kouzarides, Tony
Publication type:
Article

Found: 7

How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?

Venetoclax induces rapid elimination of NPM1 mutant measurable residual disease in combination with low‐intensity chemotherapy in acute myeloid leukaemia.

Inotuzumab ozogamicin resistance associated with a novel CD22 truncating mutation in a case of B‐acute lymphoblastic leukaemia.

MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results.

Poster: MDS-158: Updated Safety and Efficacy of Venetoclax in Combination with Azacitidine for the Treatment of Patients with Treatment-Naïve, Higher-Risk Myelodysplastic Syndromes: Phase 1b Results.

CBL mutations in chronic myelomonocytic leukemia often occur in the RING domain with multiple subclones per patient: Implications for targeting.

BET inhibitor resistance emerges from leukaemia stem cells.